← Back to Search

Alkylating agents

Ipilimumab for Mesothelioma (CheckMate743 Trial)

Phase 3

Waitlist Available

Research Sponsored by Bristol-Myers Squibb

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 40 months

Awards & highlights

CheckMate743 Trial Summary

This trial will test if a combination of two immunotherapy drugs is more effective and has fewer side effects than standard chemotherapy drugs in patients with a certain type of cancer.

Eligible Conditions

Mesothelioma

CheckMate743 Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 40 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 40 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 40 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Overall Survival (OS)

Secondary outcome measures

Disease Control Rate (DCR)

Objective Response Rate (ORR)

Objective Response Rate (ORR) According to PD-L1 Expression Level

+3 more

CheckMate743 Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: Nivolumab and IpilimumabExperimental Treatment2 Interventions

Specified dose on specified days

Group II: Pemetrexed and Cisplatin (or Carboplatin)Active Control3 Interventions

Specified dose on specified days

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Ipilimumab

2014

Completed Phase 3

~2620

Nivolumab

2014

Completed Phase 3

~4750

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Ono Pharmaceutical Co. LtdIndustry Sponsor

154 Previous Clinical Trials

93,918 Total Patients Enrolled

Bristol-Myers SquibbLead Sponsor

2,638 Previous Clinical Trials

4,127,909 Total Patients Enrolled

14 Trials studying Mesothelioma

1,339 Patients Enrolled for Mesothelioma

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What are the primary indications for Nivolumab?

"Nivolumab is an immunotherapy that can be used to treat various forms of cancer, such as malignant neoplasms, unresectable melanoma, and squamous cell carcinoma."

Answered by AI

Nivolumab has undergone FDA testing, correct?

"On our safety scale of 1 to 3, Nivolumab falls at a 3. This is due to the fact that this medication has progressed to Phase 3 trials, where there is some data supporting efficacy as well as multiple rounds of data affirming its safety."

Answered by AI

Are people currently being recruited to participate in this trial?

"Although this specific trial is not looking for new patients, the same clinicaltrials.gov website indicates that there are 2097 other studies currently recruiting."

Answered by AI

At how many different locations is this experiment being conducted today?

"This trial has 23 enrolling patients, with locations such as Local Institution - 0007 in Cleveland, Local Institution - 0005 in Houston, and University Of Chicago in Chicago."

Answered by AI

How many people have signed up to participate in this trial?

"Presently, this study is not recruiting patients that fit the eligibility criteria. The trial was first posted on 11/29/2016 and updated on 9/1/2022. For individuals seeking other studies, there are 158 trials actively looking for mesothelioma participants and 1939 Nivolumab studies with open recruitment."

Answered by AI

Could you tell me about other times Nivolumab has been used in research?

"Nivolumab was first studied in 1997 at City of Hope Comprehensive Cancer Center. Out of the 2101 completed clinical trials, a large number are still ongoing; 1939 to be precise. A significant concentration of these live trials are based in Cleveland, Ohio."

Answered by AI

Recent research and studies

The LancetJournal

First-line Nivolumab Plus Ipilimumab in Unresectable Malignant Pleural Mesothelioma (checkmate 743): A Multicentre, Randomised, Open-label, Phase 3 Trial

Baas, Paul, Arnaud Scherpereel, Anna K Nowak, Nobukazu Fujimoto, Solange Peters, Anne S Tsao, Aaron S Mansfield, et al.. 2021. “First-line Nivolumab Plus Ipilimumab in Unresectable Malignant Pleural Mesothelioma (checkmate 743): A Multicentre, Randomised, Open-label, Phase 3 Trial”. The Lancet. Elsevier BV. doi:10.1016/s0140-6736(20)32714-8.

OncologyJournal

FDA Approves Nivolumab Plus Ipilimumab for Previously Untreated Unresectable Malignant Pleural Mesothelioma

“FDA Approves Nivolumab Plus Ipilimumab for Previously Untreated Unresectable Malignant Pleural Mesothelioma”. 2020. “FDA Approves Nivolumab Plus Ipilimumab for Previously Untreated Unresectable Malignant Pleural Mesothelioma”. Oncology. MJH Life Sciences. doi:10.46883/onc.2020.3411.0502.

Annals of OncologyJournal

First-line Nivolumab Plus Ipilimumab Versus Chemotherapy in Patients with Unresectable Malignant Pleural Mesothelioma: 3-year Outcomes from Checkmate 743

Peters, S., A. Scherpereel, R. Cornelissen, Y. Oulkhouir, L. Greillier, M.A. Kaplan, T. Talbot, et al.. 2022. “First-line Nivolumab Plus Ipilimumab Versus Chemotherapy in Patients with Unresectable Malignant Pleural Mesothelioma: 3-year Outcomes from Checkmate 743”. Annals of Oncology. Elsevier BV. doi:10.1016/j.annonc.2022.01.074.

Lung CancerJournal